<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733144</url>
  </required_header>
  <id_info>
    <org_study_id>201900874</org_study_id>
    <secondary_id>2019-004983-23</secondary_id>
    <nct_id>NCT04733144</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Prednisolone and Dexamethasone</brief_title>
  <acronym>CORE</acronym>
  <official_title>An Bioequivalence Study of Prednisolone and Dexamethasone; Corticosteroids Revised - The CORE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two different glucocorticoids, prednisolone and&#xD;
      dexamethasone at two different doses for their organ specific effects, utilizing modern day&#xD;
      standards.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: A randomised, double blind, cross-over clinical trial.&#xD;
&#xD;
      Study population: healthy human adult volunteers including 12 males and 12 females aged 18-75&#xD;
      years old.&#xD;
&#xD;
      Intervention: In random order, subjects will receive 7,5 mg prednisolone for one week,&#xD;
      directly followed by 30 mg of prednisolone for one week. After a washout period of 4 weeks&#xD;
      (or by exception 8 weeks), subjects will receive 1,125 mg dexamethasone for one week,&#xD;
      directly followed by 4,5 mg dexamethasone for one week.&#xD;
&#xD;
      Main study parameters/endpoints: The main study endpoint is the difference in total urinary&#xD;
      cortisol excretion as measured in 24h-urine between the lower doses of prednisolone and&#xD;
      dexamethasone as well as between the higher doses of prednisolone and dexamethasone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suppression of the hypothalamic-pituitary-adrenal axis - low dose</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>Difference in HPA-axis suppression as measured by the difference of total urinary cortisol excretion in 24h-urine between 7,5 mg prednisolone and 1,125 mg dexamethasone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suppression of the hypothalamic-pituitary-adrenal axis - high dose</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>Difference of total urinary cortisol excretion in 24h-urine between 30 mg prednisolone (preceded by 7,5 mg prednisolone for one week) and 4,5 mg dexamethasone (preceded by 1,125 mg dexamethasone for one week)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in hypothalamic-pituitary-adrenal axis suppression - 1</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>Effect of a dosage increase from low dose to high dose prednisolone on total urinary cortisol excretion in 24h-urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hypothalamic-pituitary-adrenal axis suppression - 2</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>Effect of a dosage increase from low dose to high dose dexamethasone on total urinary cortisol excretion in 24h-urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of the hypothalamic-pituitary-adrenal axis - plasma cortisol</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in plasma cortisol levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of the hypothalamic-pituitary-adrenal axis - ACTH</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in adrenocorticotropic hormone levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of the hypothalamic-pituitary-adrenal axis - metabolites of the 24h-urine steroid profile</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in metabolites of the 24h-urine steroid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of the hypothalamic-pituitary-gonadal axis - androgen profile</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in androgen profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of the hypothalamic-pituitary-gonadal axis - gonadotropins</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in luteinizing hormone and follicle stimulating hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of the hypothalamic-pituitary-gonadal axis - metabolites of the 24h-urine steroid profile</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in metabolites of the 24h-urine steroid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of the immune system - granulocyte count</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in granulocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of the immune system - PBMCs</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in peripheral blood mononuclear cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on blood pressure</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the Renin-angiotensin-aldosterone system - plasma renin</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in plasma renin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the Renin-angiotensin-aldosterone system - aldosterone</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in aldosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the Renin-angiotensin-aldosterone system - plasma potassium</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in plasma potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the Renin-angiotensin-aldosterone system - 24h-urine potassium</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in 24h-urine potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the Renin-angiotensin-aldosterone system - trans-tubular potassium gradient</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in trans-tubular potassium gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters - OGTT</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in oral glucose tolerence tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters - lipid profile</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters - NEFAs</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in non-esterified fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in 24h urinary creatinine excretion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in handgrip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters - Weight</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in weight in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters - Body Mass Index (BMI)</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in BMI in kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters - Waist circumference</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in waist circumference in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters - Hip circumference</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in hip circumference in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires - Quality of life</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in quality of life, measured using the 36-Item Short Form Health Survey (SF-36). The score ranges from 0-100, with lower scores indicating a worse health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Serious) Adverse Events</measure>
    <time_frame>1 week per treatment</time_frame>
    <description>The between-group difference in (serious) adverce events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Prednisolone-Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 1 week of low dose (7,5 mg) prednisolone directly followed by 1 week of high dose prednisolone (30 mg). After a wash-out period, participants in this arm will receive 1 week of low dose dexamethasone (1,125 mg) directly followed by 1 week of high dose dexamethasone (4,5 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone-Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 1 week of low dose (1,125 mg) dexamethasone directly followed by 1 week of high dose dexamethasone (30 mg). After a wash-out period, participants in this arm will receive 1 week of low dose prednisolone (7,5 mg) directly followed by 1 week of high dose prednisolone (30 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)</description>
    <arm_group_label>Dexamethasone-Prednisolone</arm_group_label>
    <arm_group_label>Prednisolone-Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>1,125 mg dexamethasone 4,5 mg dexamethasone</description>
    <arm_group_label>Dexamethasone-Prednisolone</arm_group_label>
    <arm_group_label>Prednisolone-Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be healthy with no relevant medical history and no use of&#xD;
             medication.&#xD;
&#xD;
          -  Female participants aged &lt;50 years must be using oral contraceptives and female&#xD;
             participants age ≥50 years must be in the postmenopausal state&#xD;
&#xD;
          -  Command of the Dutch language&#xD;
&#xD;
          -  Providing written IC&#xD;
&#xD;
          -  BMI between 18.5 and 30 kg/m2&#xD;
&#xD;
          -  Participants must be between 18 and 75 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Potential participants who are unlikely to adhere to the study protocol (for instance&#xD;
             subjects which have a history of substance abuse or non-compliance)&#xD;
&#xD;
          -  Potential participants with a medical history of:&#xD;
&#xD;
               1. Diseases affecting the HPA-axis: e.g. primary and secondary adrenal&#xD;
                  insufficiency, pituitary tumors, and nightshift workers&#xD;
&#xD;
               2. Diseases affecting the HPG-axis: e.g. Cushing disease.&#xD;
&#xD;
               3. Chronic inflammatory diseases: e.g. rheumatoid arthritis, polymyalgia rheumatic,&#xD;
                  and asthma&#xD;
&#xD;
               4. Psychiatric diseases&#xD;
&#xD;
               5. Diabetes&#xD;
&#xD;
          -  Shift workers&#xD;
&#xD;
          -  Potential participants with a kidney function &lt;60 ml/min/1.73m2, abnormalities in&#xD;
             liver enzymes, and/or abnormalities in thyroid function&#xD;
&#xD;
          -  Potential participants who are dependent on corticosteroids, e.g. asthmatic patients,&#xD;
             and transplant recipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André P. van Beek, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan J.L. Bakker, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suzanne P. Stam, MD</last_name>
    <phone>0031503617293</phone>
    <email>s.p.stam@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne P. Stam, MD</last_name>
      <phone>0031503617293</phone>
      <email>s.p.stam@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Annet Vulto, MD</last_name>
      <phone>0031503617293</phone>
      <email>a.vulto@umcg.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>A.P. van Beek, MD PhD</investigator_full_name>
    <investigator_title>Dr. A.P. van Beek, Endocrinologist, Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

